Market Overview:
The global bladder cancer therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market is segmented on the basis of type, application, and region. On the basis of type, the bladder cancer therapeutics market is segmented into transitional cell bladder cancer, invasive bladder cancer, superficial bladder cancer, squamous cell bladder cancer and others. Transitional cell carcinoma (TCC) accounts for majority share in terms of type in global Bladder Cancer Therapeutics Market followed by invasive carcinoma and Squamous Cell Carcinoma (SCC). However; SCC is expected to grow at highest CAGR over forecast period due to increasing incidence rates across globe.
Product Definition:
A bladder cancer therapeutic is a drug or other treatment used to cure or manage bladder cancer. Bladder cancer therapeutics are important because they can help improve the quality of life for people with the disease and may also extend their life.
Transitional Cell Bladder Cancer:
Transitional cell bladder cancer (TCC) is a rare type of urinary cancer that develops from the urothelium. The disease accounts for approximately 1% of all cancers in men and 0.5% in women worldwide, with an incidence rate of around 14 cases per 100,000 people every year.
Invasive Bladder Cancer:
Invasive bladder cancer is the most common type of urinary cancer. It accounted for around 60% of all cases in men and 80% in women worldwide. The incidence rate is expected to rise with age as it mostly affects people below 65 years of age.
Application Insights:
The other application segment held the largest share of around 69.0% in 2017 owing to the increasing prevalence of bladder cancer and rising demand for effective treatment options. The other applications include urology clinics and hospitals, private practices, as well as home healthcare services.
The hospital application segment is expected to witness lucrative growth over the forecast period due to a rise in number of patients seeking medical consultation for various symptoms associated with urinary tract infections (UTIs). Bladder cancer often goes undetected until it has spread beyond control; this factor is anticipated to drive demand for hospital-based therapies during the forecast period. In addition, an increase in investment by governments across various regions towards building new hospitals or upgrading existing facilities would also boost market growth over the coming years.
Invasive bladder cancer accounted for a significant share within high risk group (HRG) population owing to early detection difficulty caused due its low grade nature coupled with late introduction of effective treatment modalities such as chemotherapy.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased research activities, and high healthcare expenditure in this region. Moreover, a higher prevalence of bladder cancer is also expected to contribute towards regional growth over the forecast period. For instance, as per statistics provided by American Cancer Society in 2018; around 1 million people will be diagnosed with bladder cancer and almost 45 thousand people will die due to this disease during the year 2020 alone.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing disposable income levels.
Growth Factors:
- Increasing incidence of bladder cancer
- Growing demand for better and advanced therapies for bladder cancer treatment
- Rising awareness about bladder cancer and its symptoms
- Technological advancements in the field of bladder cancer therapeutics
- Availability of government funding for research on bladder cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Bladder Cancer Therapeutics Market Research Report
By Type
Transitional Cell Bladder Cancer, Invasive Bladder Cancer, Superficial Bladder Cancer, Squamous Cell Bladder Cancer, Others
By Application
Hospitals, Clinics, Other
By Companies
Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
217
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Bladder Cancer Therapeutics Market Report Segments:
The global Bladder Cancer Therapeutics market is segmented on the basis of:
Types
Transitional Cell Bladder Cancer, Invasive Bladder Cancer, Superficial Bladder Cancer, Squamous Cell Bladder Cancer, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Eli Lilly
- F. Hoffman-La Roche
- Pfizer
Highlights of The Bladder Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Transitional Cell Bladder Cancer
- Invasive Bladder Cancer
- Superficial Bladder Cancer
- Squamous Cell Bladder Cancer
- Others
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bladder Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bladder cancer therapeutics are medications or treatments that are used to treat bladder cancer. These therapies can include chemotherapy, radiation therapy, and surgery.
Some of the key players operating in the bladder cancer therapeutics market are Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Pfizer.
The bladder cancer therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bladder Cancer Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bladder Cancer Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bladder Cancer Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bladder Cancer Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bladder Cancer Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Bladder Cancer Therapeutics Market Size and Y-o-Y Growth
4.5.2 Bladder Cancer Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Bladder Cancer Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bladder Cancer Therapeutics Market Size Forecast by Type
5.2.1 Transitional Cell Bladder Cancer
5.2.2 Invasive Bladder Cancer
5.2.3 Superficial Bladder Cancer
5.2.4 Squamous Cell Bladder Cancer
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bladder Cancer Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bladder Cancer Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bladder Cancer Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bladder Cancer Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bladder Cancer Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Bladder Cancer Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bladder Cancer Therapeutics Market Size Forecast by Type
9.6.1 Transitional Cell Bladder Cancer
9.6.2 Invasive Bladder Cancer
9.6.3 Superficial Bladder Cancer
9.6.4 Squamous Cell Bladder Cancer
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bladder Cancer Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bladder Cancer Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Bladder Cancer Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bladder Cancer Therapeutics Market Size Forecast by Type
10.6.1 Transitional Cell Bladder Cancer
10.6.2 Invasive Bladder Cancer
10.6.3 Superficial Bladder Cancer
10.6.4 Squamous Cell Bladder Cancer
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bladder Cancer Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bladder Cancer Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bladder Cancer Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bladder Cancer Therapeutics Market Size Forecast by Type
11.6.1 Transitional Cell Bladder Cancer
11.6.2 Invasive Bladder Cancer
11.6.3 Superficial Bladder Cancer
11.6.4 Squamous Cell Bladder Cancer
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bladder Cancer Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bladder Cancer Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Bladder Cancer Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bladder Cancer Therapeutics Market Size Forecast by Type
12.6.1 Transitional Cell Bladder Cancer
12.6.2 Invasive Bladder Cancer
12.6.3 Superficial Bladder Cancer
12.6.4 Squamous Cell Bladder Cancer
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bladder Cancer Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bladder Cancer Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bladder Cancer Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bladder Cancer Therapeutics Market Size Forecast by Type
13.6.1 Transitional Cell Bladder Cancer
13.6.2 Invasive Bladder Cancer
13.6.3 Superficial Bladder Cancer
13.6.4 Squamous Cell Bladder Cancer
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bladder Cancer Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bladder Cancer Therapeutics Market: Competitive Dashboard
14.2 Global Bladder Cancer Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 Eli Lilly
14.3.3 F. Hoffman-La Roche
14.3.4 Pfizer
